Impact of a therapeutic educational program on quality of life in Alzheimer's disease : results of a pilot study

Manuscript Number: 

14-1179

Author(s): 
Charlotte Dupuy, Fati Nourhashemi, Amelie Perrin, Bruno Vellas, Helene Villars

Disclosures

Charlotte Dupuy

  • Nothing to Disclose

Fati Nourhashemi

  • Nothing to Disclose

Amelie Perrin

  • Nothing to Disclose

Bruno Vellas

  • Consulting Fees:
    Astra-Zénéca, Eisai, Elan, Exhonit, GSK, Lilly, Medivation, MSD, Nestlé, Nutricia, Pfizer, Pierre-Fabre, Roche, Sanofi, Servier, TauRx Therapeutics, Wyeth
    Grants
    • Agency: 
      Abbvie
      Dates: 
      2014
    • Agency: 
      Affiris
      Dates: 
      2014
    • Agency: 
      Wyeth
      Dates: 
      2014
    • Agency: 
      TauRx Therapeutics
      Dates: 
      2014
    • Agency: 
      Servier
      Dates: 
      2014
    • Agency: 
      Sanofi
      Dates: 
      2014
    • Agency: 
      Roche
      Dates: 
      2014
    • Agency: 
      R_g_n_ron
      Dates: 
      2014
    • Agency: 
      Pierre-Fabre
      Dates: 
      2014
    • Agency: 
      Pfizer
      Dates: 
      2014
    • Agency: 
      Pharnext
      Dates: 
      2014
    • Agency: 
      Otsuka
      Dates: 
      2014
    • Agency: 
      Nutricia
      Dates: 
      2014
    • Agency: 
      MSD
      Dates: 
      2014
    • Agency: 
      Medivation
      Dates: 
      2014
    • Agency: 
      Lilly
      Dates: 
      2014
    • Agency: 
      Avid
      Dates: 
      2014
    • Agency: 
      Ipsen
      Dates: 
      2014
    • Agency: 
      GSK
      Dates: 
      2014
    • Agency: 
      Genentech
      Dates: 
      2014
    • Agency: 
      Exhonit
      Dates: 
      2014
    • Agency: 
      Envivo
      Dates: 
      2014
    • Agency: 
      BMS
      Dates: 
      2014
    • Agency: 
      Eisai
      Dates: 
      2014
    • Agency: 
      Elan
      Dates: 
      2014

Helene Villars

  • Nothing to Disclose